MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Código da empresaMNKD
Nome da EmpresaMannKind Corp
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Número de funcionários407
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 28
Endereço1 Casper Street
CidadeDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Telefone18186615000
Sitehttps://mannkindcorp.com/
Código da empresaMNKD
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados